Here are 23 recent drug shortages and discontinuations, according to the FDA’s drug supply databases:
Discontinued
- Ampicillin sodium injection: Multiple private-label strengths were discontinued Dec. 8.
- Calcitriol capsule: The 0.25-microgram and 0.5-microgram strengths were discontinued Dec. 4 as a business decision.
- Sodium chloride 0.9% injection: Several presentations, including ADD-Vantage containers, were discontinued Dec. 3.
- Posaconazole injection: The 18-mg/mL dose of Noxafil was discontinued Dec. 2.
- Nilutamide tablet: All 150-milligram presentations of Nilandron were discontinued Dec. 1.
- Phenoxybenzamine hydrochloride capsule: All 10-milligram presentations of Dibenzyline were discontinued Dec. 1.
In shortage
- Amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine saccharate and dextroamphetamine sulfate tablet
- Azacitidine injection
- Carboplatin injection
- Clindamycin phosphate injection
- Furosemide injection
- Hydromorphone hydrochloride injection
- Ketorolac tromethamine injection
- Lisdexamfetamine dimesylate capsule
- Methotrexate sodium injection
- Methylphenidate hydrochloride extended-release tablet
- Nitroglycerin injection
- Rocuronium bromide injection
- Streptozocin powder for solution
- Parathyroid hormone injection
- Remifentanil hydrochloride injection
- Sodium bicarbonate injection
- Sterile water injection
